Late Breaking Clinical Trials 1 PCI, FFR and cost

[LB1-1] Prasugrel effectively reduces PRU in patients with genetically metabolic dysfunction of CYP2C19 who are treated with long-term DAPT

^○佐々木 健一郎¹, Shimamatsu Junichiro^1,2, Katsuki Yoshio³, Kawasaki Tomohiro⁴, Murasato Yoshinobu⁵, Yokoi Hiroyoshi⁶, Tashiro Hideki⁷, Harada Atsushi⁸, Hirakawa Yuji⁸, Ishizaki Yuta¹, Ishimatsu Takashi¹, Kagiyama Kotaro¹, Fukumoto Yoshihiro¹, Kakuma Tatsuyuki⁹, Ueno Takafumi¹ (1.久留米大学医学部 心臓・血管内科, 2.Division of Cardiovascular Internal Medicine, Tanushimaru Chuo Hospital, Kurume, Japan, 3.Division of Cardiology, Sugi Hospital, Omuta, Japan, 4.Department of Cardiology, Cardiovascular Center, ShinKoga Hospital, Kurume, Japan, 5.Department of Cardiology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, 6.Division of Cardiovascular Internal Medicine, Fukuoka Sanno Hospital, Fukuoka, Japan, 7.Division of Cardiovascular Internal Medicine, St.Mary's Hospital, Kurume, Japan, 8.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 9.Biostatistics Center, Kurume University, Kurume, Japan)

同通あり